Shergis JL, et al. - In this multicentre, randomised, double-blind, placebo-controlled trial, researchers compared the efficacy and safety of ginseng to that of placebo in people with moderate COPD (aged 40 years and over). Participants had airflow limitation in the moderate (Global Initiative for Chronic Obstructive Lung Disease 2) COPD range and were administered ginseng capsules (100 mg twice daily) or placebo for 24 weeks. They randomised 1:1 168 participants from five centres in Australia and China. Findings revealed that improvement in health-related quality of life (primary outcome) observed between the ginseng and placebo groups was not significantly different.